ArticleClinical cancer research : an official journal of the American Association for Cancer Research2012
Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 3 syntheses or guidelines pooled it, 142 citations in OpenAlex.
- A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas.Scientific reports · 2018Pooled it
- Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma.British journal of cancer · 2015Pooled it
- Systematic review and meta-analysis of tumor biomarkers in predicting prognosis in esophageal cancer.BMC cancer · 2013Pooled it
- Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 Trial.JCO precision oncology · 2025Trial
- HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2015Trial
- Article
- Identification of necrosis-related signature for predicting prognosis and immunotherapy response in gastric cancer.Translational cancer research · 2026Article
- Antibody-Mediated Therapy in Gastric Cancer: Past, Present, and Future.Current issues in molecular biology · 2025Review
- Near-Infrared Photoimmunotherapy Targeting Esophagogastric Junction Adenocarcinoma With Fully Human Anti-EpCAM Antibody.Cancer science · 2025Article
- Potential diagnostic, prognostic, and predictive biomarkers of gastric cancer.Health science reports · 2024Article
- Molecular Pathology of Gastroesophageal Cancer.Clinics in laboratory medicine · 2024Review
- Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study.International journal of clinical oncology · 2024Article
- Genomic Variations in Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma.Cureus · 2023Article
- Cancer Risk in Barrett's Esophagus: A Clinical Review.International journal of molecular sciences · 2023Review
- Deviating HER2 test results in gastric cancer: analysis from the prospective multicenter VARIANZ study.Journal of cancer research and clinical oncology · 2023Article
- A comparative study of gastric adenocarcinoma HER2 IHC phenotype and mass spectrometry-based quantification.Frontiers in oncology · 2023Article
- Fructose-1,6-bisphosphatase 1 (FBP1) is an independent biomarker associated with a favorable prognosis in esophageal adenocarcinoma.Journal of cancer research and clinical oncology · 2022Article
- Clinical Significance of TRIM44 Expression in Patients with Gastric Cancer.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells.Nature · 2022Article
- Comparative genomic analysis of esophageal squamous cell carcinoma and adenocarcinoma: New opportunities towards molecularly targeted therapy.Acta pharmaceutica Sinica. B · 2022Review
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
purposeWe examined the frequency, tumor characteristics, and prognostic impact of HER2 protein expression and gene amplification in patients with curatively resected esophageal adenocarcinoma (EAC). EXPERIMENTAL
designHER2 expression was analyzed by immunohistochemistry (IHC) in surgical EAC specimens (n = 713). Gene amplification was examined by FISH in a large subset (n = 344). Most tumors were T3-4 (66%) or node positive (72%); 95% were located in the esophagus or gastroesophageal junction. No patient received neoadjuvant therapy. Cox models were used.
resultsOverall, 17% of EACs were HER2 positive (i.e., IHC3(+) or IHC2(+) with amplification), with strong agreement between HER2 amplification (HER2/CEP17 ratio ≥2) and expression (κ = 0.83). HER2 positivity was significantly associated with lower tumor grade, less invasiveness, fewer malignant nodes, and the presence of adjacent Barrett's esophagus (BE). EACs with BE had higher odds of HER2 positivity than EACs without BE, independent of pathologic features [OR = 1.8 (95% CI: 1.1-2.8), P = 0.014]. Among all cases, HER2 positivity was significantly associated with disease-specific survival (DSS) in a manner that differed by the presence or absence of BE (P(interaction) = 0.0047). In EACs with BE, HER2 positivity was significantly associated with improved DSS [HR = 0.54 (95% CI: 0.35-0.84), P = 0.0065] and overall survival (P = 0.0022) independent of pathologic features, but was not prognostic among EACs without BE.
conclusionsHER2 positivity was shown in 17% of resected EACs and associated with reduced tumor aggressiveness. EACs with BE had nearly twice the odds of being HER2 positive and, within this subgroup, HER2 positivity was independently associated with improved survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.